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Abstract 25	  
The use of fused-filament 3D printing (FF 3DP) to fabricate individual tablets is 26	  
demonstrated. The technology permits the manufacture of tablets containing drug 27	  
doses tailored to individual patients, or to fabrication of tablets with specific drug-28	  
release profiles. Commercially produced polyvinyl alcohol (PVA) filament was loaded 29	  
with a model drug (Fluorescein) by swelling of the polymer in ethanolic drug solution. 30	  
A final drug-loading of 0.29% w/w was achieved. Tablets of PVA/Fluorescein (10 mm 31	  
diameter) were printed using a 3D printer. It was found that changing the degree of 32	  
infill percentage in the printer software varied the weight and volume of the printed 33	  
tablets. The tablets were mechanically strong and no significant thermal degradation 34	  
of the active occurred during printing. Dissolution tests were conducted in modified 35	  
Hank’s buffer. The results showed release profiles were dependent on the infill 36	  
percentage used to print the tablet. The study indicates that FF 3DP has the potential 37	  
to offer a new solution for fabricating personalized-dose medicines or unit dosage 38	  
forms with controlled-release profiles. In addition, the low cost of FDM printers means 39	  
the paradigm of extemporaneous or point-of-use manufacture of personalized-dose 40	  
tablets is both feasible and attainable. 41	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Introduction 46	  
The need to formulate drugs that have narrow therapeutic indices (for instance 47	  
immunosuppressants or blood thinners), the increasing importance of proteomic and 48	  
metabolomic analyses and the concomitant development of drugs and drug 49	  
combinations personalised to the patient, are powerful drivers shaping the future of 50	  
medicine design. In particular, the development of medicines personalised to the 51	  
patient requires consideration of novel manufacturing technologies capable of 52	  
fabricating small numbers of dosage forms, because current commercial technology 53	  
only operates efficiently on a large scale. Printing technology has much potential in 54	  
this area because it is possible to print drug solutions onto substrates (ink-jet printing) 55	  
and to fabricate dosage forms directly (3D printing).  56	  
Ink-jet printing is particularly suited to deposition of drug solutions onto flat 57	  
substrates, such as oral wafers (Buanz et al, 2011). The technology has been used 58	  
to manufacture modified-release or personalized-dose medicines by printing dots of 59	  
solution onto a substrate (Scoutaris et al 2011, 2012) and it has been shown possible 60	  
to fabricate three-dimensional particles by printing aqueous droplets into liquid 61	  
nitrogen and subsequently freeze-drying (Mueannoom et al, 2012; Sharma et al, 62	  
2013). 63	  
It is 3D printing (3DP) technology however that offers perhaps the greatest potential 64	  
to revolutionize the future of pharmaceutical manufacturing (Yu et al, 2008; Wang, 65	  
2013). 3DP was developed as a tool for rapid prototyping. Typically a layer of a 66	  
powdered substrate is spread over a build plate and a binding solution is deposited 67	  
using an x-y printhead (analogous to ink-jet printing) to consolidate the powder. The 68	  
object is then built up layer-by layer. This type of system has been widely employed 69	  
to manufacture pharmaceutical dosage forms, including zero-order release tablets 70	  
(Wang et al, 2006) and implants (Bbureck et al, 2007; Huang et al, 2007). The ability 71	  
to change the powder and so manufacture multi-layer tablets has also been 72	  
demonstrated (Katstra et al, 2000a,b; Yu et al, 2007). One limitation of this design is 73	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that it cannot print hollow objects, because free powder will always be contained in 74	  
the cavity, although even this effect has been exploited to fabricate fast-dissolving 75	  
devices comprising powder contained in a polymeric shell (Yu et al, 2009a,b). An 76	  
alternative technology is selective laser sintering (SLS), in which a laser is used to 77	  
cure a photopolymer (this technology is used to print personalised medical devices, 78	  
such as hearing aid shells). 79	  
The most recent 3DP technology is fused-filament (FF) printing, wherein a polymer 80	  
strand is heated and extruded through a small tip (typically 50-100 µm) and then 81	  
solidified on a build plate. FF technology has the significant advantages of cost 82	  
(typical systems cost between £800-2000), the ability to fabricate hollow objects and 83	  
the utility to print a range of polymers. The printer feedstock is an extruded polymer 84	  
filament, typically 1.75 – 3 mm in diameter. One of the prime benefits of FF 3DP is 85	  
that it is possible in principle to incorporate drug into the polymer filament so that the 86	  
printed dosage form is drug loaded. 87	  
To our knowledge, there has been no demonstration on the use of FF printing to 88	  
manufacture drug-loaded unit dosage forms, although recent work using a similar 89	  
system to print a paste has been reported (Khaled et al, 2014). Hence, the specific 90	  
aims of this work were evaluate a method to load drug into the polymer filament, to 91	  
print drug-loaded tablets using an FF 3DP and to explore whether varying the print 92	  
settings enabled control over the dissolution kinetics of the final tablet and so offer a 93	  
new method of manufacturing controlled-release dosage forms. Fluorescein was 94	  
selected as a model drug because of its thermal stability and ease of quantification.  95	  
 96	  
Materials and Methods 97	  
Polyvinyl alcohol (PVA, a water-soluble synthetic polymer of formula (C2H4O)n) was 98	  
purchased as an extruded filament (1.75mm diameter, print temperature 190-220°C, 99	  
batch No: 2013-10-18, Makerbot Inc., USA). Absolute ethanol was of analytical grade. 100	  
Fluorescein sodium salt was obtained from Sigma-Aldrich, Poole, UK. Salts for 101	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preparing buffer dissolution media were purchased from VWR International Ltd., 102	  
Poole, UK. 103	  
 104	  
Preparation of PVA filament loaded with fluorescein: PVA filaments (~5 m in length) 105	  
were placed in an ethanolic solution of fluorescein (2% w/v) with magnetic stirring for 106	  
24h. The drug-loaded filaments were removed and dried in an oven to constant 107	  
weight (1.5h at 60°C) and stored in a vacuum desiccator until printing. The drug-load 108	  
was determined with HPLC (see below).   109	  
 110	  
Printing of Fluorescein tablets: Tablets were fabricated with a MakerBot Replicator 2x 111	  
Desktop 3D printer (MakerBot Inc, USA). The templates used to print the tablets 112	  
were designed with MakerWare Software (v. 2.2.2). The selected size for the tablet 113	  
was X=10 mm, Y=10 mm and Z=3.6 mm (Figure 1). The printer settings that were 114	  
found to produce the best tablets were standard resolution without the raft option 115	  
activated, extrusion temperature (220 °C), speed while extruding (90mm/s), speed 116	  
while traveling (150mm/s), number of shells (2) and layer height (0.20mm). The infill 117	  
percentage was varied (0%, 10%, 25%, 50% or 90%, 100%) in order to produce 118	  
tablets of different weights and infill patterns (Table 1 and Figure 2)  119	  
 120	  
Determination of tablet morphology: The diameter and thickness of the tablets were 121	  
measured using a digital calliper. Pictures were taken with a Nikon CoolpixS6150 122	  
with the macro option of the menu. Additional pictures of fluorescein tablets were 123	  
taken in a dark room under UV light (Mineralight® Lamp UVGL-58, USA) at a 124	  
wavelength of 365nm to evaluate the distribution of fluorescein in the tablets. 125	  
 126	  
Determination of fluorescein concentration: One tablet or a drug-loaded strand before 127	  
printing (approx. 0.3g) was placed in a 1L volumetric flask containing bicarbonate 128	  
buffer with magnetic stirring until complete dissolution. Samples were then filtered 129	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through 0.22 µm filters (Millipore Ltd, Ireland). Concentrations of fluorescein were 130	  
determined at 490nm with a Cary 100 UV-VIS spectrophotometer (Agilent 131	  
Technologies, UK). Measurements were performed in duplicate. 132	  
 133	  
Dissolution testing: Drug release profiles from printed tablets were determined with a 134	  
USP-II apparatus (Model PTWS, Pharmatest, Germany). In each assay, tablets were 135	  
placed at the bottom of the vessel and were stirred (50 rpm) in dissolution medium 136	  
(900 mL) at 37°C. Tests were conducted in triplicate under sink conditions. During 137	  
the dissolution test, samples were automatically removed and filtered through 0.1mm 138	  
filters and fluorescein concentration was determined using an in-line UV 139	  
spectrophotometer (Cecil 2020, Cecil Instruments Ltd., Cambridge, UK) operated at 140	  
490nm. Data were processed using Icalis software (Icalis Data Systems Ltd, 141	  
Berkshire, UK). Experiments were conducted in a dark room to avoid photo-142	  
degradation of fluorescein. 143	  
Dissolution tests were performed in a modified bicarbonate buffer (pH 6.8) controlled 144	  
by an Auto pH SystemTM (Merchant et al, 2012). The bicarbonate buffer was chosen 145	  
because of its better resemblance to the physiological characteristics of 146	  
gastrointestinal fluid than phosphate buffers (Fadda et al, 2005; Liu et al, 2011). The 147	  
medium, adapted from Hank’s buffer, is primarily a bicarbonate buffer, in which 148	  
bicarbonate (HCO3-) and carbonic acid (H2CO3) co-exist in equilibrium, along with 149	  
dissolved CO2, resulting from the dissociation of the latter (Equation 1). 150	  
 151	  
Equation 1 152	  
 153	  
	  
	  	  	  	  	  	  	  	  	  	  	  CO2  (g)	  
	  H2O   + CO2(aq)  	  	   	   H2CO3	   	   	   H+   + HCO3−	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Adjusting the concentration of carbonic acid (H2CO3) and bicarbonate (HCO3-) in 154	  
accordance with the Henderson-Hasselbalch equation (Equation 2) allows control of 155	  
the buffer pH. 156	  
 157	   𝑝𝐻 = 𝑝𝐾𝑎 + log    [!"#!!][!!!"!]   158	  
Equation 2 159	  
Purging the solution with carbon dioxide, which promotes the formation of carbonic 160	  
acid, increases the carbonic acid concentration. Similarly, purging with an inert gas 161	  
(such as Helium) reduces the carbonic acid to bicarbonate ratio, which removes 162	  
dissolved CO2 from the solution and so pushes the equilibrium to the left. The 163	  
purging of gases is regulated by an Auto pH SystemTM, automatically triggered by a 164	  
pH feedback from solution. Controlling the pH of the medium to pH 6.8 simulates the 165	  
pH conditions of the small intestine. Additionally, other components are added to 166	  
simulate the ionic strength and composition of gastrointestinal fluid (136.9 mM NaCl, 167	  
5.37 mM KCl, 0.812 mM MgSO4.7H2O, 1.26 mM CaCl2, 0.337 mM Na2HPO4.2H2O, 168	  
0.441 mM KH2PO4, 4.17 mM NaHCO3, CO2 quantity sufficient to maintain the pH at 169	  
6.8). 170	  
 171	  
Results and discussion 172	  
Tablets were fabricated initially using the commercially available extruded PVA 173	  
polymer, prior to any drug loading, in order to assess the suitability and capability of 174	  
the printer. Tablets were produced with a high degree of repeatability of weight and 175	  
physical dimension (Table 1 and Figure 2). Tablets were mechanically strong enough 176	  
to handle without damage and, although they are not discussed in this paper, it was 177	  
possible to create tablets of varying size using the scaling factor in the printer driver 178	  
software. This immediately indicates that FF 3DP has the potential to offer a new 179	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manufacturing solution for fabricating personalized-dose medicines, since scaling the 180	  
tablet to the appropriate volume or weight would permit fabrication of specific doses. 181	  
In addition, the low cost of FF printers means the paradigm of extemporaneous or 182	  
point-of-use manufacture of personalized-dose tablets would appear to be both 183	  
feasible and attainable. 184	  
Of course, to fabricate pharmaceutically relevant tablets it is necessary to incorporate 185	  
a drug into the polymer filament, prior to the fabrication step. Fluorescein was 186	  
selected as it has a low molecular weight, good solubility in a range of solvents and a 187	  
convenient UV chromophore for analysis. Additionally, its fluorescence under UV 188	  
light meant it was possible to image the filament before and after printing and so 189	  
determine the location of the drug in the polymer. Since the PVA polymer used here 190	  
is commercially available pre-extruded for the printer, drug was loaded into the 191	  
polymer from solution. In this method, the polymer filament is swelled in a solution of 192	  
drug for a period of time before removal and drying. In principle, and assuming no 193	  
chemical interaction between the drug and polymer, the drug should passively diffuse 194	  
into the polymer matrix and be trapped following the drying phase. The method has 195	  
the considerable advantage that the diameter of the polymer filament is the same 196	  
before and after drug loading, which means the printer easily extrudes it. It is also 197	  
cheap, versatile and requires little method development, save selection of a suitable 198	  
solvent. 199	  
It was not possible to load the drug into the polymer from aqueous solution, because 200	  
the PVA filament started to dissolve with 10 min and did not return to its original 201	  
geometric size and morphology on drying. This was not unexpected because the 202	  
polymer was not chemically cross-linked. Drug loading from ethanol was found to be 203	  
more successful, because the polymer filament did not dissolve, even after 24h. 204	  
However, the final drug-loading was relatively low 0.29 ± 0.01 % w/w. Further, the 205	  
fluorescein is seen mainly towards the surface of the strands (Figure 3), indicating 206	  
relatively slow diffusion of the drug into the polymer. It is important to note here that 207	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the main aim of this work was to assess the feasibility of 3DP as a method to 208	  
fabricate unit dosage forms and so while the loading efficiency was low, sufficient 209	  
drug was present to enable dissolution analysis. Clearly, loading drug from other 210	  
solvents may result in higher encapsulation and/or greater diffusion into the polymer 211	  
strands. 212	  
One further point of interest is that analysis of the printed tablets showed a drug 213	  
content of 0.28 ± 0.02 % w/w. This demonstrates that the drug was not degraded as 214	  
it passed through the heated extruder of the printer (fluorescein melting temperature, 215	  
320 oC). It is important to recognise, however, that the relatively high extrusion 216	  
temperature of PLA means 3DP may not be universally suitable for thermally labile 217	  
drugs. 218	  
The tablet template was imported into the Makerware software prior to printing as a 219	  
stereolithography (.stl) file. This file type encodes only the surface data (or shell) of 220	  
the object to be printed. It is necessary for the 3DP software to define the thickness 221	  
of the shell (so that there is an object of some physical size to be printed) but in 222	  
essence a hollow object will be printed. To increase the mechanical strength of the 223	  
object, the user can select an infill percentage to be used during printing (the infill 224	  
percentage is the degree to which the printer will pack the void space with polymer 225	  
and will vary from 0, empty, to 100, solid). Greater infill percentages will result in 226	  
stronger objects. It follows that there is the potential to use the infill percentage to 227	  
modulate the physical properties of the 3DP tablet, and so the dissolution profile. 228	  
Here, tablets were printed with six different infill percentages (0, 10, 25, 50, 90 and 229	  
100%). Tablets with 0% infill were hollow because only the shell was printed. Tablets 230	  
with 10%, 25% and 50% infill showed different internal patterns. These patterns got 231	  
more dense as the infill value increased. 90% infill tablets showed no cavities and 232	  
appeared as a compact mass. Photographs of selected tablets are shown in the 233	  
cross-section images in Figure 4. 234	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It is worth noting that the fluorescein is distributed uniformly inside the tablets, the 235	  
implication being that during printing the softening of the polymer allows uniform 236	  
redistribution of the fluorescein. 237	  
It can be seen from Table 1 and the photographs in Figure 4 that the tablet weights 238	  
and physical dimensions increased with increasing infill percentage. There is a very 239	  
good linear relationship between the infill and the tablet weight (r2 = 0.9741), 240	  
suggesting that it could also be possible to control the drug dose by varying the infill 241	  
percentage. The infill percentage also slightly increased the thickness of the tablets 242	  
(the lengths remain almost constant). 243	  
For dissolution testing tablets were selected with low (10%), medium (50%) and high 244	  
(90%) infill. Dissolution tests were conducted in modified Hank’s bicarbonate buffer 245	  
(pH 6.8), more representative of human small intestinal fluid. It is apparent that the 246	  
dissolution profiles show different behaviours. Faster drug release was seen with a 247	  
lower infill percentage (Figure 5). The 10% infill tablets show complete release after 6 248	  
h, while 50% and 90% tables release fluorescein over an extended time period (77% 249	  
and 70% drug release after 6 h respectively). Complete drug dissolution took 15h for 250	  
50% infill tablets and 20h for 90% infill tablets. Gupta et al (2011) showed that the 251	  
swelling ratio of PVA hydrogels was dependent on polymer concentration, higher 252	  
concentrations resulting in reduced swelling ratios and this effect may be controlling 253	  
the release profiles seen in this work. 254	  
Pictures of tables obtained after dissolution show a reduction of size and an 255	  
apparently homogenous distribution of the drug inside the tablet during the 256	  
dissolution process (Figure 6). According to the pictures, the release of the drug 257	  
seems to be mediated mainly by an erosion process. 258	  
 259	  
Conclusion 260	  
We have demonstrated the feasibility of using FF 3DP to fabricate drug-loaded 261	  
tablets and have shown that the release profiles obtained can be modified by careful 262	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selection of the printing parameters. The results immediately suggest that FF printng 263	  
could offer a potential new method of manufacture for personalised-dose medicines 264	  
and/or for tablets prepared at the point of dispensation/use. Our initial study loaded 265	  
drug into polymer filament by passive diffusion from solution and while the 266	  
percentage drug loading was low, it was sufficient to demonstrate proof-of-principle. 267	  
It was possible to print tablets of varying physical size and density and it has been 268	  
shown that infill percentage modulates the dissolution profile.  269	  
 270	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Table 1: Measured parameters of the printed fluorescein tablets as a function of infill 336	  
percentage (n=9) 337	  
 338	  
Infill (%) Weight (mg) 
Thickness 
(mm) 
Major length 
(mm) 
Minor length 
(mm) 
Theoretical 
Volume 
(mm3) 
0 216.5 ±3.1 3.48 ±0.01 10.67 ± 0.04 10.66 ±0.06 310.88 
10 229 ±2.6 3.71 ±0.05 10.50 ±0.08 10.63 ±0.08 325.24 
25 245.3 ±0.6 3.74 ±0.07 10.48 ±0.02 10.57 ±0.02 325.39 
50 266.6 ±2.8 3.78 ± 0.05 10.45 ±0.04 10.58 ±0.05 328.25 
90 285.7 ±7.7 4.03 ±0.15 10.48 ±0.07 10.63 ±0.06 352.62 
100 293.6 ±8.0 4.34 ±0.04 10.55 ±0.04 10.59 ±0.07 353.98 
 339	  
 340	  
 341	  
  342	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 343	  
Figure 1: The basic tablet design, rendered in Makerware v2.2.2. 344	  
 345	  
  346	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 347	  
 348	  
 349	  
Figure 2: Images of 3DP fabricated tablets as a function of infill percentage, 350	  
showing (from left to right; top, base, internal and lateral views) 351	  
 352	  
  353	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 354	  
 355	  
 356	  
Figure 3: Images of polymer filaments as received (left) and after loading with 357	  
fluorescein (right) under UV light. 358	  
  359	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 360	  
 361	  
 362	  
 363	  
Figure 4: Cross-sectional views of 3DP fabricated tablets containing 364	  
fluorescein under UV light (top 10%, middle 50%, bottom 90%) 365	  
 366	  
  367	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 368	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 369	  
Figure 5: Dissolution profiles of 3DP tablets with varying infill percentages in 370	  
modified Hank’s buffer (pH 6.8) 371	  
 372	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 374	  
 375	  
 376	  
Figure 6: Tablet integrities as a function of dissolution time (2, 4, 6 and 8h) 377	  
showing fluorescein is released via erosion (top 10%, middle 50%, bottom 90%) 378	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